FDA 510(k) Clearance Explained: A Practical Guide for Medical Device Startups

What Every Medical Device Startup Needs to Know Before Filing a 510(k)

If you're developing a medical device and planning to enter the U.S. market, the FDA's 510(k) premarket notification pathway is likely your most direct route to clearance. Yet for many startups and early-stage device companies, the process remains opaque, misunderstood, or chronically underestimated in its complexity. Submitting a 510(k) without a clear strategy doesn't just waste time — it can cost hundreds of thousands of dollars and delay your commercial launch by a year or more.

This guide breaks down how the 510(k) pathway actually works, what FDA is looking for, and the practical steps you need to take to get it right the first time.

What Is a 510(k) and Who Needs One?

Under Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and codified in 21 CFR Part 807 Subpart E, manufacturers must demonstrate to FDA that their device is substantially equivalent to a legally marketed predicate device before introducing it to U.S. commerce. This applies to most Class II devices and some Class I devices that do not qualify for exemption.

Substantial equivalence does not mean your device is identical to the predicate. It means your device has the same intended use and the same — or different but not raising new safety concerns — technological characteristics. This is a critical distinction that trips up many first-time filers.

FDA recognizes three types of 510(k) submissions: Traditional, Abbreviated, and Special. Most startups file Traditional 510(k)s, but if a recognized consensus standard applies to your device, an Abbreviated 510(k) may streamline your path by relying on declarations of conformity to those standards.

Selecting the Right Predicate Device

Predicate selection is arguably the most consequential decision in your entire 510(k) strategy. A poorly chosen predicate can force you into performance testing you weren't prepared for, or worse, result in a Not Substantially Equivalent (NSE) determination.

Your predicate must be a legally marketed device — meaning it was cleared via a prior 510(k), was on the market before May 28, 1976 (a pre-amendments device), or received De Novo authorization. Preamendments devices listed in FDA's database can serve as predicates but require careful validation of their legal marketing status.

When evaluating predicates, review the 510(k) summary or decision summary in FDA's 510(k) database (accessible at FDA.gov) for any device you intend to reference. Understand not just what the predicate claimed, but what testing it submitted — because FDA may expect you to meet or exceed that evidentiary bar.

What Goes Into a 510(k) Submission

FDA's Refuse to Accept (RTA) Policy for 510(k)s guidance document outlines the administrative completeness checklist reviewers apply before your submission enters substantive review. Failing RTA adds 15 or more days before your review clock even starts.

A complete Traditional 510(k) submission includes, at minimum:

• Device description — detailed specifications, materials, components, and principles of operation
• Substantial equivalence comparison — a side-by-side analysis of your device versus the predicate across intended use and technological characteristics
• Performance testing — bench testing, biocompatibility per ISO 10993, sterilization validation, electrical safety and EMC per applicable IEC standards, and software documentation if applicable
• Labeling — draft labeling compliant with 21 CFR Part 801
• Software documentation — if your device contains software, FDA's Guidance on the Content of Premarket Submissions for Device Software Functions (2023) defines documentation requirements based on your software's level of concern
• Clinical data — not always required for 510(k), but when your device differs significantly from the predicate in technological characteristics, clinical performance data may be necessary to establish substantial equivalence

Common Mistakes That Delay Clearance

After working with dozens of device companies across diagnostics, digital health, surgical instruments, and capital equipment, the same failure patterns appear repeatedly:

• Predicate mismatch — claiming substantial equivalence without adequately addressing technological differences, resulting in Additional Information (AI) requests that pause your review clock
• Inadequate biocompatibility documentation — submitting a materials list instead of a risk-based biocompatibility evaluation as required under the updated ISO 10993-1:2018 standard and FDA's 2016 guidance
• Software under-documentation — underestimating the software level of concern or failing to include a Software Bill of Materials (SBOM) when FDA reviewers now routinely expect it
• Late-stage testing gaps — discovering performance test failures after submission, which forces withdrawal and resubmission

Timeline and FDA Review

FDA's target review time for a standard 510(k) is 90 days from acceptance under MDUFA performance goals. In practice, most submissions receive at least one AI request, which pauses the clock — extending real-world timelines to five to nine months for many devices. eSTAR (Electronic Submission Template and Resource), now required for most 510(k) submissions, has improved consistency but does not eliminate the need for strategic preparation.

When 510(k) May Not Be the Right Path

Not every device is eligible for 510(k). If your device has no valid predicate, presents novel risks, or FDA determines your technological differences raise new questions of safety and effectiveness, you may face a De Novo request or be required to pursue Premarket Approval (PMA) under 21 CFR Part 814. Understanding which pathway applies to your device before you begin development — not after — is one of the highest-value regulatory decisions you can make.

Build Your Regulatory Strategy Early

The companies that reach FDA clearance fastest are not necessarily the ones with the most resources. They are the ones that engage regulatory strategy early, select the right predicate with clear rationale, design their testing program to match submission requirements, and manage FDA communications proactively.

At ADB Consulting & CRO Inc., we work directly with startup founders, VP-level regulatory and quality leaders, and product teams to develop submission-ready 510(k) strategies grounded in current FDA expectations — not outdated templates. Whether you're determining your device classification, building your predicate strategy, or preparing for a first submission, we bring the regulatory depth to move your program forward with confidence.

Ready to map out your 510(k) pathway? Book a free discovery call with Andre Butler and the ADB Consulting team at adbccro.com. Let's talk about where your device stands and what it will take to get to clearance.